| ORION-E4, the Second Phase 3 Trial of Oral Valiltramiprosate, Aims to Confirm Clinical Benefits Observed in the APOLLOE4 MCI Subgroup in APOE4/4 Patients with Mild Cognitive Impairment The post Alzheon Highlights ORION-E4 Phase 3 Trial Launch for Oral Valiltramiprosate/ALZ-801 and Expansion of Its Oral Anti-Amyloid Aggregation Inhibitor Portfolio at CTAD 2026 Conference in Boston, November 16–19 appeared first on Alzheon | Preserving Future Memories . |